Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.

ABSTRACT:

Background

Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies. The discovery of ALK activating mutations opened the way to precision treatment in a subset of these patients. Previously, we investigated the transcriptional effects of pharmacological ALK inhibition on neuroblastoma cell lines, six hours after TAE684 administration, resulting in the 77-gene ALK signature, which was shown to gradually decrease from 120 minutes after TAE684 treatment, to gain deeper insight into the molecular effects of oncogenic ALK signaling.

Aim

Here, we further dissected the transcriptional dynamic profiles of

SUBMITTER: Claeys S 

PROVIDER: S-EPMC5739776 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature